Keros Therapeutics, Inc. — Director's Dealing 2021

Mar 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-02-26

Reporting Person: Lachey Jennifer (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-26	Common Stock	M	33200	$0.11	Acquired	61191	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-26	Employee Stock Option (right to buy)	$0.11	M	33200	Disposed	2027-02-05	Common Stock (33200)	Direct

Footnotes

F1: One-quarter (1/4th) of the shares subject to the option vested on July 1, 2017, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date